PHILADELPHIA, June 15, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the “Company” or “Hemispherx”), announced that the Company executed an exclusive revenue sharing Sales, Marketing, Distribution and Supply Agreement for Argentina with GP Pharm Latinoamerica (“GP Pharm”), an affiliate company of Spanish GP Pharm SA (www.gp-pharm.com). Under this Agreement, GP Pharm will be responsible for gaining regulatory approval in Argentina for Ampligen®, an experimental therapeutic, to treat Chronic Fatigue Syndrome (“CFS”) in Argentina and for commercializing Ampligen® for this indication in Argentina. The Company has granted GP Pharm the right to expand rights to sell this experimental therapeutic into other Latin America countries based upon GP Pharm achieving certain performance milestones. The Company has also granted GP Pharm an option to market Alferon N Injection®, its FDA approved natural interferon, in Argentina and other Latin America countries as well. Under this Agreement, the Company will manufacture and supply Ampligen® to GP Pharm.
